Nuvalent Inc - Asset Resilience Ratio
Nuvalent Inc (NUVL) has an Asset Resilience Ratio of 84.72% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Nuvalent Inc's Asset Resilience Ratio has changed over time. See NUVL free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Nuvalent Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NUVL market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.13 Billion | 84.72% |
| Total Liquid Assets | $1.13 Billion | 84.72% |
Asset Resilience Insights
- Very High Liquidity: Nuvalent Inc maintains exceptional liquid asset reserves at 84.72% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nuvalent Inc Industry Peers by Asset Resilience Ratio
Compare Nuvalent Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for Nuvalent Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Nuvalent Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 78.59% | $1.11 Billion | $1.41 Billion | -6.60pp |
| 2024-12-31 | 85.19% | $972.61 Million | $1.14 Billion | +32.68pp |
| 2023-12-31 | 52.50% | $384.52 Million | $732.38 Million | +4.76pp |
| 2022-12-31 | 47.75% | $230.36 Million | $482.46 Million | -26.99pp |
| 2021-12-31 | 74.73% | $219.59 Million | $293.82 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $10.65 Million | -- |
About Nuvalent Inc
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine k… Read more